Direct effects of exendin-(9,39) and glp-1-(9,36)amide on insulin action, b-cell function, and glucose metabolism in nondiabetic subjects

Diabetes

Volumn 62, Issue 8, 2013, Pages 2752-2756

  Sathananthan, Matheni ^a   Farrugia, Luca P ^a   Miles, John M ^a   Piccinini, Francesca ^b   Man, Chiara Dalla ^b   Zinsmeister, Alan R ^a   Cobelli, Claudio ^b   Vella, Adrian ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN (9,39); GLP 1 (9,36)AMIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; EXENDIN (9-39); GLUCAGON; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; GLUCOSE BLOOD LEVEL; PEPTIDE; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CELL FUNCTION; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; INSULIN ACTION; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BODY MASS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET BETA CELL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 84891684054     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0140     Document Type: Article

References (25)

1. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142:521-27
2. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80: 952-957
3. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1- (7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003;88:1772-1779
4. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 2003;114:153-158
5. D'Alessio DA, Vogel R, Prigeon R, et al. Elimination of the action of glucagon- like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996;97:133-138
6. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9- 39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-1430
7. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-251
8. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Goke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21:609-618, e21-22
9. Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008;16:1501-1509
10. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989;111:671-674
11. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000;49:611-617
12. Bradley DC, Steil GM, Bergman RN. Quantitation of measurement error with Optimal Segments: basis for adaptive time course smoothing. Am J Physiol 1993;264:E902-E911
13. Steele R, Bjerknes C, Rathgeb I, Altszuler N. Glucose uptake and production during the oral glucose tolerance test. Diabetes 1968;17:415-421
14. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15-24
15. Campioni M, Toffolo G, Basu R, Rizza RA, Cobelli C. Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters. AmJ Physiol Endocrinol Metab 2009;297:E941-E948
16. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004;36:830-836
17. Ban K, Kim K-H, Cho C-K, et al. Glucagon-like peptide (GLP)-1(9-36)amidemediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531
18. Sathananthan A, Dalla Man C, Zinsmeister AR, et al. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) 2012;76:212-219
19. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 2005;54:1649-1656
20. Ahrén B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 2005;48:2140-2146
21. Pacini G, Thomaseth K, Ahrén B. Dissociated effects of glucosedependent insulinotropic polypeptide vs. glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Metabolism 2010;59: 988-992
22. Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab 2007;293:E849-E856
23. Brandt A, Katschinski M, Arnold R, Polonsky KS, Göke B, Byrne MM. GLP-1- induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 2001;281:E242-E247
24. Nielsen MF, Dinneen S, Basu A, Basu R, Alzaid A, Rizza RR. Failure of nocturnal changes in growth hormone to alter carbohydrate tolerance the following morning. Diabetologia 1998;41:1064-1072
25. Dinneen S, Alzaid A, Miles J, Rizza R. Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am J Physiol 1995;268:E595-E603